Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIVOT hydroxyurea trial in HbSC disease
PACTR202108893981080Phase 2Completed
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Nov 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of hydroxyurea in sickle cell disease (SCD) (2 arms), sponsored by Cincinnati Children's Hospital Medical Center. Primary endpoints: Safety of hydroxyurea in HbSC disease and Identification of measurable laboratory and clinical changes. Started Nov 2021; status: completed.
02
Drugs
hydroxyurea
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on PACTR202108893981080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202108893981080.